ArticleEcancermedicalscience2025
Presentation, treatment and clinical outcomes in young multiple myeloma patients treated at a tertiary care centre in a low middle-income country.
Article in Ecancermedicalscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Multiple myeloma (MM), a plasma cell malignancy, predominantly affects individuals aged 65-74 years. However, its occurrence in younger populations (<55 years) is rare, posing unique challenges. This study explores the clinical presentation, outcomes and treatment regimens for MM patients aged 30-55, aiming to unravel age-specific patterns. Methods: A retrospective chart review was conducted at Aga University Hospital, Karachi, focusing on MM patients aged 30-55 years. Data included patient demographics, clinical features, treatment modalities and outcomes. Statistical analysis employed STATA version 16.0, incorporating survival estimates, log-rank tests and Cox proportional survival regression models. Results: This study encompassed 68 confirmed MM patients, categorised by age groups: 30-40 years (13.23%), 41-50 years (44.11%) and 51-55 years (42.64%). Predominantly male (1.3:1 ratio), bone pains were prevalent among all groups, with 51-55 years exhibiting the highest pathological fracture rate. 30-40 years group showed higher renal impairment rates and lactate dehydrogenase levels. Velcade, thalidomide and dexamethasone were commonly used first-line regimens in the entire cohort in 41.17% of patients, closely followed by cyclophosphamide, bortezomib and dexamethasone in 29.41%. Partial response was predominant in the 30-40 years group, while other age groups showed varied responses. The younger patients demonstrated lower deep treatment response rates than their older counterparts. Progression-free survival was 37, 52 and 45 months orderly in each group, with a Conclusion: This single-center study sheds light on younger MM patients' unique challenges and treatment patterns. Despite the rarity of this age group's affliction, the findings underscore significant differences in clinical presentations, treatment responses and outcomes compared to the typical elderly MM population. The study highlights the importance of tailored approaches in managing MM across different age brackets, emphasising the need for further research to optimise therapeutic strategies and improve prognosis in this distinct patient cohort.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.